Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Liabilities (2024 - 2025)

Historic Other Non-Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 2 years, with Q1 2025 value amounting to $3.8 million.

  • Corvus Pharmaceuticals' Other Non-Current Liabilities changed N/A to $3.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.8 million, marking a year-over-year change of. This contributed to the annual value of $28.9 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Other Non-Current Liabilities of $3.8 million as of Q1 2025.
  • Corvus Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $40.0 million for Q3 2024, and its period low was $3.8 million during Q1 2025.